Research_Medicine Person Daniel :
Hengrui Pharmaceuticals, a super large transaction, newco. BD&L: pipeline of Hercules Company in the United States, candidate new drugs of GLP-1 product portfolio (overseas equity), including: (1) HRS-7535, small molecule GLP-1 receptor agonist; （2）HRS953
Research_Medicine Person Daniel :
Shijiazhuang Pharmaceutical Holding Co., Ltd. Shijiazhuang Pharmaceutical Group Co., Ltd. Hunan Jingfeng Pharmaceutical Co., Ltd. Unfortunately. The leaves of that year are still the same year.
Research_Medicine Person Daniel :
Kexing Bio Pharmaceutical Co., Ltd. (Kexing Pharmaceutical, 688136. SH) announced that the company had recently paid a total of 21.311 million yuan in taxes and overdue fines. Previously, the First Inspection Bureau of Jinan Municipal Taxation Bureau of the State Administration of Taxation made a report on the Company from January 1, 2021 to December 31, 2022
Research_Medicine Person Daniel :
AstraZeneca really dares to think, 80 billion dollars in 2030. Before, some domestic enterprises announced the performance of the pharmaceutical industry of 100 billion yuan in 2030
Research_Medicine Person Daniel :
WuXi AppTec Announcement: Although the U.S. government agencies have already had an assessment procedure for national security issues, the H.R.8333 draft still retains WuXi AppTec's company name in the definition of "biotechnology company to be concerned", and the company strongly opposes this kind of preset and unreasonable definition without due process. Hard
Research_Medicine Person Daniel :
Catch the small elements of the times. The third generation EGFR of Alex. In the first quarter of 2024, the revenue will be 743 million yuan, and the net profit will be 306 million yuan. It's not a big problem for single products to break through 3 billion this year.
Research_Medicine Person Daniel :
WuXi AppTec: The net profit in 2023 will be 9.6 billion yuan, up 9% year on year; It is proposed to distribute cash dividends of RMB 9.8336 per 10 shares to all shareholders, totaling RMB 2.88 billion.
Research_Medicine Person Daniel :
Shijiazhuang Pharmaceutical Group and Pfizer jointly announced that they had signed a strategic cooperation agreement on the combination packaging of locally marketed new coronavirus oral antiviral drugs, namatvir tablets/ritonavir tablets, in China. Based on this strategic cooperation, the two sides will work together to improve the accessibility of Chinese patients to Xinguan oral antiviral drugs.
Research_Medicine Person Daniel :
Enzyme (synthetic biology), BSJ, financing 250 million yuan. 2.4 billion yuan after investment$ Jinsirui Biotechnology hk01548$
Research_Medicine Person Daniel :
The listing of Hong Kong shares is a bit scary, and the first day of green bamboo is - 32%. The transaction volume was not large, 76.91 million yuan.
